Document text
Principal Investigator: Sydney Montesi
Organization: MASSACHUSETTS GENERAL HOSPITAL
Fiscal Year: 2024
Award: $177,348
Funding agency: National Heart Lung and Blood Institute
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease. Within IPF, however, there
exists marked disease heterogeneity as some patients experience a rapidly progressive course while others
experience prolonged periods of stability or stepwise declines triggered by disease exacerbations.
Unfortunately, there are no accepted means by which patients can be clinically “phenotyped” into these
different disease courses at the time of diagnosis. The ability to predict an individual patient’s pace of
progression would greatly impact patient care by enabling better prognostication, individualization of treatment
plans, and early evaluation for lung transplantation for those at highest risk of rapidly progressive disease.
Such knowledge could also be utilized as a cohort enrichment strategy allowing new IPF therapies to be
evaluated in patients at greatest risk of progression thus improving clinical trial feasibility. We hypothesize that
disease activity in IPF is driven by ongoing lung injury and that measurements of ongoing lung injury could be
utilized to predict prognosis and treatment response. Vascular leak, a cardinal response to tissue injury, has
been implicated in the development of IPF. Alveolar-capillary permeability is increased in the lungs of IPF
patients, and the extent of this increase has been shown to correlate with disease progression and mortality.
We will use the advanced magnetic resonance imaging (MRI) technique of dynamic contrast-enhanced (DCE)
MRI to assess vascular permeability in the lungs of IPF patients and healthy volunteers and prospectively
evaluate if these MRI-derived measures of lung vascular permeability predict subsequent IPF disease
progression. We will also evaluate whether increased plasma levels of soluble Ephrin-B2 (sEphrin-B2), a novel
molecular biomarker of lung injury in fibrosis, can identify IPF patients most likely to experience disease
progression. Lastly, we will perform lung DCE-MRI prior to and after initiation of anti-fibrotic therapy with
nintedanib, which we hypothesize will decrease lung vascular permeability by inhibiting vascular endothelial
growth factor (VEGF), to assess whether our MRI-derived lung vascular permeability measures are decreased
with treatment. This research will be performed by Dr. Sydney Montesi, a pulmonary and critical care physician
at Massachusetts General Hospital, an Instructor of Medicine at Harvard Medical School, and a specialist in
the care of patients with pulmonary fibrosis. She will receive first-rate training in advanced lung imaging and
biomarker development. She will be exceptionally mentored by Dr. Peter Caravan, a pioneer in molecular
imaging of fibrosis, and co-mentored by Dr. David Christiani, an expert in biomarker development for lung
injury. She will perform her research in a world-renowned academic center with all required resources available
to her. Dr. Montesi’s goal is to become a physician-scientist in patient-oriented research of pulmonary fibrosis.
This K23 award will provide her with the training and mentorship to achieve independence and apply for her
first R01.
Terms: <Acceleration><Alveolar><Blood Plasma><Blood Vessels><CAT scan><CT X Ray><CT Xray><CT imaging><CT scan><Capillary Permeability><Cell Communication and Signaling><Cell Signaling><Clinical><Clinical Research><Clinical Study><Clinical Trials><Clinical Trials Design><Cohort Studies><Computed Tomography><Concurrent Studies><Critical Care><Data><Development><Development Plans><Diagnosis><Disease><Disease Progression><Disorder><Early identification><Efbn2 Gene Product><Endothelial Cells><Endothelium><Ephrin-B2><Eplg5 Gene Product><Eplg5 Protein><Evaluation><Fibrosing Alveolitis><Fibrosis><Forced Vital Capacity><General Hospitals><Goals><High Resolution Computed Tomography><Image><Image Enhancement><Imaging Procedures><Imaging Technics><Imaging Techniques><Individual><Injury><Intracellular Communication and Signaling><K23 Award><K23 Mechanism><K23 Program><Knowledge><LERK-5 Gene Product><LERK-5 Protein><Lung><Lung Function Tests><Lung Grafting><Lung Respiratory System><Lung Tissue Fibrosis><Lung Transplantation><Lung damage><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance Imaging><Massachusetts><Measurement><Measures><Mediator><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Medicine><Mentored Patient-Oriented Research Career Development Award><Mentored Patient-Oriented Research Career Development Award (K23)><Mentors><Mentorship><Methods><Molecular><NMR Imaging><NMR Tomography><Nuclear Magnetic Resonance Imaging><Observation research><Observation study><Observational Study><Observational research><Ofev><Outcome><Patient Care><Patient Care Delivery><Patients><Permeability><Physicians><Plasma><Plasma Serum><Position><Positioning Attribute><Prognosis><Progressive Disease><Pulmonary Fibrosis><Pulmonary Graft><Pulmonary Transplant><Pulmonary Transplantation><Pulmonary function tests><Pulmonary imaging><Research><Research Infrastructure><Research Resources><Resources><Reticuloendothelial System, Serum, Plasma><Risk><Scientist><Severity of illness><Signal Transduction><Signal Transduction Systems><Signaling><Specialist><Stable Disease><Statistical Methods><Techniques><Testing><Time><Tomodensitometry><Training><VEGF><VEGFs><Vascular Endothelial Growth Factors><Vascular Permeabilities><Vital capacity><X-Ray CAT Scan><X-Ray Computed Tomography><X-Ray Computerized Tomography><Xray CAT scan><Xray Computed Tomography><Xray computerized tomography><Zeugmatography><antifibrotic agent><antifibrotic medication><antifibrotic therapy><antifibrotic treatment><biological signal transduction><biomarker development><biomarker discovery><biomarker validation><blood-brain tumor barrier><blood-tumor barrier><bloodbrain tumor barrier><care for patients><care of patients><career><career development><caring for patients><catscan><clinical phenotype><cohort><computed axial tomography><computer tomography><computerized axial tomography><computerized tomography><contrast enhanced><customized therapy><customized treatment><developmental><diffuse interstitial pulmonary fibrosis><disease heterogeneity><disease severity><experience><feasibility trial><fibrosis in the lung><healthy volunteer><high resolution CT><high risk><idiopathic pulmonary fibrosis><imaging><imaging biomarker><imaging marker><imaging-based biological marker><imaging-based biomarker><imaging-based marker><improved><in vivo><indexing><individual patient><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><injuries><injury to tissue><instructor><lung fibrosis><lung imaging><lung injury><lung scanning><lung transplant><marker validation><medical college><medical schools><molecular biomarker><molecular imaging><molecular marker><molecule imaging><mortality><nintedanib><non-contrast CT><noncontrast CT><noncontrast computed tomography><novel><novel imaging technique><patient oriented research><patient oriented study><patient specific therapies><patient specific treatment><prognostication><progression risk><prospective><pulmonary><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><response><response to therapy><response to treatment><school of medicine><skill acquisition><skill development><statistic methods><tailored medical treatment><tailored therapy><tailored treatment><therapeutic response><therapy response><tissue injury><treatment planning><treatment response><treatment responsiveness><tumor><unique treatment><vascular>